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Abstract
In principle, the technique of gene delivery involves taking complete or parts of genes that can
code specific messages and delivering them to selected cells in the body. Such a transfer of
plasmid DNA into mammalian cells has posed major challenges for gene therapy. A series of
gelatin–siloxane nanoparticles (GS NPs) with controlled size and surface charge were
synthesized through a two-step sol–gel process. In order to increase the efficiency of cellular
uptake, HIV-derived Tat peptide was further grafted to GS NPs. In vitro co-location and
endocytosis inhibition experiments suggested that the as-synthesized TG NPs may enter HeLa
cells via a combined pathway of lipid-raft- and receptor-dependent endocytosis, and only cause
little cell damage. Moreover, this study shows the encapsulation of a plasmid DNA in TG NPs
to be obtained as a non-viral gene vector. This kind of encapsulation provides complete
protection to the plasmid DNA from the external DNase and serum environment, and generates
the hope that the resulting formulation can be developed into a potential vector for effective
gene delivery. In order to check this potential, the reporter gene pSVβ-gal was encapsulated,
and in vitro transfection efficiency of this system was found to be nearly 130% compared to the
commercially available transfection reagent Lipofectamine™.
(Some figures in this article are in colour only in the electronic version)
1. Introduction
Gene transfer using non-viral vectors is a promising approach
for the safe delivery of therapeutic DNA in genetic and
acquired human diseases [1, 2]. In contrast to viral vectors,
non-viral vectors benefit from low immunogenicity, the
absence of endogenous recombination, low production costs
and reproducibility [1]. Furthermore, they have no size
limitation in DNA packaging. Unfortunately, non-viral DNA
delivery vehicles often affect cell viability and have poor
transfection efficiency. Gene expression only results when
3 Both these authors contributed equally to this work.
4 Author to whom any correspondence should be addressed.
the DNA is delivered into the cell nucleus of the target cell.
On its way, the DNA has to pass several biological barriers,
beginning with the plasma membrane, followed by avoidance
of the endosomal pathway, and finally passage through the
nuclear pores [1]. Today, there is still a huge need for carriers
that transport DNA quickly and efficiently and release it in a
controlled manner.
Currently, three different strategies for non-viral applica-
tion of therapeutic DNA have been developed. The simplest
way is the use of naked DNA, which is injected directly into the
target tissue [3], applied via electroporation or ultrasound [4].
DNA can also be loaded onto nanoparticles of heavy metals
and brought into cells by gene gun [5]. However, enzymatic
degradation of the unprotected DNA and poor cell transfection
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efficiencies limited their applications [3]. Another approach
is the use of lipoplexes that are lipid-based DNA vehicles,
entering the cytoplasm by cell membrane fusion [6]. Many
different modifications for specific cell targeting and intra-
cellular routing have been developed [6, 7]. The primary
drawback is the rapid clearance of lipoplexes in the blood
system and their short-term stability [8]. The third approach
is to use polymeric nanoparticles (NPs) [9], such as poly L-
lysine (PLL) [10], polyethyleneimine (PEI) [11], chitosan [12]
and gelatin [13] to complex plasmid DNA. Although polymers
with high cationic charge density could condense the DNA
into structures amenable to cellular internalization, both PLL
and PEI have significant toxicity that may ultimately limit
their clinical utility [14]. In addition, both chitosan and
gelatin have relatively low transfection efficiencies compared
to polycations, though they are biocompatible [13].
Besides those approaches, inorganic nanoparticles, which
possess versatile properties suitable for gene delivery, includ-
ing wide availability, rich functionality, good biocompatibility,
potential capability of targeted delivery (e.g. selectively de-
stroying cancer cells but sparing normal tissues) and controlled
release of carried drugs, have attracted much attention as
novel non-viral carriers in the last decade [15]. It is
evident that the versatility of Au nanoparticles (Au NPs)
and carbon nanotubes (CNTs) makes them very suitable as
potential delivery carriers [16, 17]. However, the transfection
efficiency of Au NP- or CNT-based gene delivery systems is
relatively low. Silica nanoparticles provide another promising
vector system for gene delivery because of their versatile
physiochemical properties, such as nanoscale size and easy
synthesis, tailorable surface charge density, facile surface
functionalization and good biocompatibility [18]. It is also
worth mentioning that Bharali et al have successfully applied
organically modified silica nanoparticles (ORMOSIL) for gene
delivery in vitro or in vivo [19].
To improve the transfection efficiency of non-viral
carriers, new strategies were put forward to enhance their
cellular uptake, among which the utilization of cell-penetrating
peptides (CPPs) attracts considerable attention for cell
biological studies and therapies [20]. CPPs are small protein
transduction domains (PTDs), generally around 10–16 amino
acids in length, that can efficiently deliver the attached
macromolecules and even nanoparticle carriers (e.g. polymers,
liposomes) into cells by crossing the biological membrane
barriers [20]. One of the representative CPPs is the Tat
peptide, which is derived from the transcriptional activator TAT
protein of the human immunodeficiency virus type-1 (HIV-
1) [21, 22]. To date researchers have shown that Tat peptides
can be internalized by most cell types, and more importantly,
allow the intracellular delivery of the conjugated cargos, being
as large as several hundred nanometers in size [20, 22–24].
The design of safe and efficient gene transfection vectors
is still a challenge in gene therapy. For the past several years,
our group has been engaged in exploring the synthesis of
porous and bioactive gelatin–siloxane (GS) hybrid scaffolds
through a combined approach of sol–gel process and freeze-
drying [25]. Those GS scaffolds might stimulate osteoblast
proliferation and differentiation in vitro, and could be used
for bone tissue engineering [25]. The objective of the present
work was the development of a gene vector on the basis of
gelatin–siloxane nanoparticles (GS NPs). HIV-1 Tat peptide
was coupled to a GS surface via sulfhydryl groups in order to
achieve efficient gene transfection and expression.
2. Materials and methods
2.1. Chemicals
Gelatin (bloom number: 240–270, pH 4.5–5.5) was pur-
chased from BBI (USA). 3-glycidoxypropyl-trimethoxysilane
(GPSM) and 3-aminopropyl-trimethoxysilane (APTMS) were
purchased from Acros Organics (USA). 2-Iminothiolane hy-
drochloride (Traut’s reagent) and 5,5′-dithio-bis-(2-nitrobenz-
oic acid)(3,3′-6) (Ellman’s reagent) were purchased from
Fluka (USA). Sodium azicle (NaN3), chlorpromazine hy-
drochloride (CpZ), ethedium bromide (EtBr), dimethyl sul-
foxide (DMSO) and ninhydrin were purchased from Sigma
(USA). 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium
bromide (MTT) and 2′-(4-hydroxyphenyl)-5-(4-methyl-1-
piperazinyl)-2,5′-bi-1H-benzimidazole (Hoechst 33258) were
purchased from Amresco (USA). 2-deoxy-D-glucose (2-DG)
and β-cyclodextrin (β-CD) were purchased from ABCR
GmbH & Co. KG Germany and Tokyo Kasei Kogyo Co. Japan,
respectively. Lipofectamine™ reagent was from Invitrogen
Co. (USA). Alexa Fluor® 546-transferrin, Alexa Fluor® 594-
Ctx B and PicoGreen® reagent were purchased from Molecular
Probe (USA). Dulbecco’s Modified Eagle’s Medium (DMEM),
fetal bovine serum (FBS) and penicillin–streptomycin were
obtained from Hyclone (USA). Npys-activated C-terminal
Cys containing Tat peptide (KYGRRRQRRKKRGC) and rho-
damine (TAMRA)/fluorescein iso-thiocyanate (FITC)-labeled
Tat peptide were provided by Chinese Peptide Co. (China).
Annexin V-FITC/propidium iodide (PI) apoptosis detection
kit and pSV β-galactosidase control vector (pSV β-gal)
colorimetric detection kit were purchased from Alexis (USA)
and Genmed Scientific Inc. (USA), respectively. All materials
used were of analytical grade and used without further
purification. The glassware were thoroughly cleaned and
rinsed with deionized water.
2.2. Purification of plasmid DNA
Plasmid DNA (pSV β-galactosidase control vector, pSVβ-
gal) encoding β-galactosidase was purchased from Promega
Co. (USA). The plasmid was amplified by being transformed
into Escherichia coli and then purified by a standard alkaline
lysis technique. The pDNA showed a high purity as the
260 nm/280 nm absorption ratio was between 1.8 and 2.0.
2.3. Preparation of TG NPs
Tat peptide decorated gelatin–siloxane nanoparticles (TG NPs)
was synthesized in three steps. Gelatin–siloxane nanoparticles
(GS NPs) were first prepared by a two-step sol–gel procedure.
Briefly, the appropriate amount of GPSM was added to a
1% gelatin solution in HCl (pH 3.0) at 50 ◦C. After stirring
for 30 min, APTMS were subsequently added into the above
2
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Table 1. Composition and characteristics of GS, TG and TG/DNA nanoparticles. (Note: GS: gelatin–siloxane nanoparticles; TG: Tat peptide
decorated GS nanoparticles.)
















GS G1 38.5 59.1 1.9 222 ± 7 0.31 ± 0.05 22.40 ± 2.80
G2 115.4 154.1 3.0 / / 362 ± 8 0.34 ± 0.03 23.30 ± 5.07
G3 133.3 177.3 3.0 319 ± 3 0.27 ± 0.03 28.00 ± 5.89
G4 115.4 177.3 1.9 165 ± 5 0.15 ± 0.04 24.54 ± 2.69
TG T1 0.63 197 ± 0 0.27 ± 0.01 34.92 ± 1.47
T2 115.4 177.3 1.9 1.58 / 167 ± 9 0.24 ± 0.01 36.16 ± 2.98
T3 2.84 189 ± 2 0.26 ± 0.01 36.38 ± 1.41
TG/DNA D1 0.63 100/1 339 ± 9 0.28 ± 0.01 22.03 ± 0.40
D2 1.58 100/1 213 ± 2 0.17 ± 0.04 21.40 ± 0.99
D3 115.4 177.3 1.9 2.84 100/1 318 ± 9 0.29 ± 0.03 20.77 ± 0.87
D4 1.58 50/1 880 ± 12 0.46 ± 0.06 13.07 ± 0.30
D5 1.58 20/1 1137 ± 33 0.31 ± 0.09 −6.53 ± 0.15
a n = 5.
mixture. The composition of the precursor sols studied was
shown in table 1. Though the mixture was initially clear,
continuous stirring gave a milky emulsion. The resulting GS
NPs were then obtained by centrifugation for 15 min at 30 ◦C,
19 000 rpm, and washed three times with deionized water.
In the second step, introduction of sulfhydryl (–SH)
groups on GS NPs was achieved by a previous method [26].
Briefly, Traut’s reagent was added to 7 mg ml−1 of
GS NPs suspension in 50 mmol l−1 potassium phosphate
buffer solution (pH 8.0) to get a weight ratio of GS
NPs/Traut’s reagent = 8:1. The mixture was then incubated
for 24 h at 25 ◦C under continuous stirring.
Thirdly, the obtained SH–GS NPs suspension was directly
mixed with synthetic Tat peptide (1 mg ml−1) at various
Tat/GS NPs ratios. The mixture was further incubated for 2
d at room temperature under continuous stirring in darkness.
TG NPs were finally obtained by centrifugation for 15 min
at 30 ◦C, 19 000 rpm, and washed three times with deionized
water. The reaction scheme is shown in scheme 1.
2.4. Preparation of TG/DNA nanocomplexes
TG NPs suspension were finally mixed with DNA solution
at predetermined TG/DNA ratios, followed by 30 s vortex
and 30 min incubation. TG NPs/pDNA (TG/DNA)
complexes were purified by centrifugation for 15 min at 30 ◦C,
19 000 rpm, and washed three times with deionized water. In
the following experiments, TG/DNA complexes were finally
re-dispersed in deionized water and the final concentration of
pDNA was kept at 100 μg ml−1 for each sample.
2.5. Physicochemical characterization
2.5.1. Particle size analysis and zeta potential measurement.
TG NPs or TG/DNA nanocomplexes were re-dispersed in
deionized water and the volume of each sample was 1 ml.
Surface charges (zeta potentials) and sizes of each sample were
measured on a Nano-ZS Zetasizer dynamic light scattering
detector (Malvern Instruments, UK) equipped with a 4.0 mW
internal laser. At least five measurements were performed for
each sample at 25 ◦C at a scattering angle of 90◦. The effective
particle diameters were calculated from the autocorrelation
function using the Malvern Zetasizer software assuming a log
normal distribution.
2.5.2. Quantitative estimation of amino groups. Total
amino group (–NH2) levels on the surface of GS NPs were
quantitatively determined with the ninhydrin colorimetric
reaction [27]. Briefly, 0.4 ml of GS NPs suspension
(1 mg ml−1) was mixed with 0.4 ml of ninhydrin solution
(2%, ethanol solvent) and 1.2 ml of phosphate buffer (pH
8.0, 50 mmol l−1). The mixture was then refluxed in a
water bath at 100 ◦C for 15 min. After cooling down
to room temperature, the resulting solution was collected
for photometrically analysis at 450 nm by a UV–visible
spectrophotometer (DUTM800, Beckman Coulter, USA). The
amount of –NH2 groups was calculated from the relevant
standard curve of histidine with a linear range of quantification
from 0 to 1.5 mmol l−1 (r 2 = 0.9855).
2.5.3. Thiolation assay. After modifying with Traut’s
reagent, the degree of thiolation of GS NPs was determined
by Ellman’s reaction. This method is well described in the
literature [26]. Briefly, the un-reacted Traut’s reagent was
removed from the SH–GS NPs suspension by centrifugation
for 15 min at 30 ◦C, 19 000 rpm, and washed three times with
deionized water. 120 μl of Ellman’s (1 mg ml−1) reagent was
then added to 1.22 ml of SH–GS suspension (0.09 mg ml−1)
in PBS (0.5 mol l−1, pH 8.0) After reacting for 2 h at room
temperature the absorbance of the mixture was then measured
at a wavelength of 420 nm by a UV–visible spectrophotometer
(DUTM800, Beckman Coulter, USA). Non-modified GS NPs
served as a negative control group. The amount of thiol
moieties was calculated from the corresponding standard curve
elaborated between 0 and 1.5 mmol l−1 of L-cysteine (r 2 =
0.9954).
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Scheme 1. Synthesis of Tat peptide decorated gelatin–siloxane nanoparticles.
2.5.4. Spectrofluorimetry quantitative analysis. For
fluorescence measurements, TAMRA-labeled Tat peptide was
used in the synthesis processing. The supernatant of the
resulting TG NPs suspension was collected and subsequently
analyzed by a fluorescence spectrophotometer (Hitachi 650–
10 s, Japan). The excitation and emission wavelengths were
546 nm and 576 nm, respectively. The linear range of
quantification between 1 and 50 mg ml−1 of TAMRA-labeled
Tat peptide was determined in deionized water (r 2 = 0.986).
The measurements were performed in duplicate and repeated
three times. The conjugating ratio of Tat to GS NPs was
assessed as follows:
Tat/GS (mol g−1) = (MO − MU)/MNPs
where MO and MU represent the amount (mol) of the original
and un-reacted Tat peptide, respectively; MNP represents the
amount (g) of TG NPs.
2.5.5. Quantitative DNA release assay. The pDNA-
loaded TG NPs were separated from the free pDNA by
centrifugation for 15 min at 30 ◦C, 19 000 rpm, and washed
three times with deionized water. For quantitative release
assay, TG/DNA nanocomplexes were respectively added to
50, 150 and 300 mmol l−1 NaCl aqueous solution up to 24 h,
and the concentration of pDNA in each suspension was kept
at 20 μg ml−1. At various time points, the supernatant of
each suspension was collected and pipetted into TE buffer
at 1:9 (v/v). The pDNA concentrations were then estimated
by using PicoGreen® reagent, following the manufacturer’s
protocol. The fluorescence intensity was measured by a
fluorescence spectrophotometer (Hitachi F-4500, Japan) at
480 nm excitation and 520 nm emission wavelengths. The
linear range of quantification between 0 and 1 μg ml−1 of
pSV β-gal was determined in deionized water (r 2 = 0.997).
All experiments were performed in triplicate, and the release
degree (%) of pSV β-gal was expressed as a percentage relative
to the loaded pDNA on TG NPs.
2.5.6. Surface-enhanced Raman spectroscopy (SERS). For
in situ SERS measurement, a gold electrode was immersed
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in a TG suspension (10 mg ml−1) for 15 min, followed by
air drying. All Raman spectra were acquired on a confocal
microprobe Raman system (Labram I, Jobin Yvon, France).
In the present study, the sizes of the slit and pinhole were
respectively set at 100 and 800 μm, and the acquisition time
was set to 60 s. A 632.8 nm He–Ne laser was used as
the excitation line, with a power of 2.5 mW on the sample.
The microscope objective for laser illumination and signal
collection was of long working distance (8 mm) with 50×
magnification and a numerical aperture of 0.55.
2.5.7. Laser confocal scanning microscopy (CLSM)
characterization. For CLSM observation, FITC-labeled Tat
peptide was used in the synthesis processing. A drop of
the resulting TG NPs suspension (1 mg ml−1) was deposited
onto a glass slide and air-dried prior to microscopy analysis.
The specimen was then excited at 488 nm for FITC on
an inverted laser confocal scanning microscope (Fluoview
FV1000, Olympus, Japan) using a Plan-Apochromat 60 × 0.7
NA lens. Images were analyzed with the Fluoview 1.5 Viewer
software.
2.6. Gel retardation assay
To confirm the DNA condensation ability of TG NPs, gel
electrophoresis was performed. Nanocomplex formation was
induced at various TG/DNA weight ratios from 20 to 100. 8 μl
of nanocomplexes (3.5 mg ml−1) were loaded onto 1% agarose
gels with EtBr (500 ng ml−1) and run with Tris-acetate (TAE)
buffer at 150 V for 45 min. DNA retardation was observed by
irradiation with a gel documentation system (Tanon GIS-2008,
China).
Protection and release of DNA in complexes were
also carried out by gel electrophoresis. 100 μl of
TG/DNA complexes (3.5 mg ml−1) or naked plasmid DNA
(200 μg ml−1) were first incubated with 1 U DNase I and 10%
FBS in PBS buffer, as well as 50, 150 and 300 mmol l−1 NaCl
aqueous solution at 37 ◦C, 200 rpm for 15 min, respectively.
The mixed suspension (8 μl) was then electrophoresed in 1%
agarose gel with TAE running buffer for 45 min at 150 V, and
the gels were finally viewed by a gel documentation system
(Tanon GIS-2008, China).
2.7. In vitro studies
HeLa cells (ATTC CCL2) were cultured in DMEM (high
glucose) supplemented with 10% heat-inactivated FBS and 1%
penicillin/streptomycin. The cells were maintained at 37 ◦C in
a humidified 5% CO2-containing atmosphere.
2.7.1. MTT assay. In vitro cytotoxicity of the TG NPs
complexes was analyzed by the MTT assay. HeLa cells were
seeded at a density of 1 × 105 cells per well in polystyrene
96-well culture plates, and incubated for 24 h till the 70%
confluence. After removing the culture medium, 100 μl
of serum-free DMEM medium containing TG NPs (100–
600 μg ml−1) was then added to each well. Cells treated with
medium only served as a negative control group. After 24 h
co-incubation, the medium was replaced with 20 μl of MTT
solution (5 mg ml−1 in PBS buffer) and further cultured for 4 h.
At the end of the assay, MTT solution was removed and 100 μl
of DMSO was added to dissolve the blue formazan crystal
produced by proliferating cells. The plate was incubated
for an additional 10 min before determination at 490 nm
in a spectrophotometric microplate reader (Bio-tek ELX800,
USA). All experiments were performed in quadruplicate, and
the relative cell viability (%) was expressed as a percentage
relative to the untreated control cells.
2.7.2. Cell apoptosis assay. Apoptosis/necrosis induced
by TG NPs was assayed by an annexin V-FITC/PI
apoptosis detection kit, which comprises two individual
stains: (1) annexin V has a strong Ca2+-dependent affinity
for phosphatidylserine which might translocate from the
cytoplasmic face of the plasma membrane to the cell surface
during apoptosis and (2) PI is membrane-impermeant and
generally excluded from viable cells, but could intercalate
into double-stranded nucleic acids [28]. HeLa cells were
first seeded onto 6-well plates at a density of 5 × 104 cells
per well and left overnight to adhere. The medium was
then replaced with the culture medium containing TG NPs.
After co-culturing for 24 h, HeLa cells were harvested and
incubated with 200 μl of binding buffer (HEPES buffered PBS
supplemented with 2.5 mmol l−1CaCl2), 2 μl of annexin V-
FITC and 5 μl of PI at room temperature for 15 min in the
dark, following the manufacturer’s instructions. After a final
wash in PBS, HeLa cells were immediately analyzed on an
EPICS XL flow cytometer (Beckman Coulter, USA), gated
on live cells by FSC/SSC. Samples were excited by the light
wavelength of 488 nm with barrier filters of 525 nm and
575 nm for FITC fluorescence and PI detection, respectively.
Data were analyzed by EPICS XL flow cytometer software
and plotted for annexin V-FITC and PI in a two-way dot
plot. Live, early apoptotic and late apoptotic/necrotic cells
are designed as annexin −/PI−, annexin +/PI− and annexin
+/PI+, respectively.
2.7.3. Cellular uptake. HeLa cells (3×105) were treated with
FITC-labeled TG NPs (100 μg ml−1) in serum-free DMEM
for 5 h. The adherent HeLa cells were trypsinized to detach
from the petri dish, and subsequently re-suspended in ice-cold
PBS buffer solution. The fluorescent cells with FITC-labeled
TG NPs were then measured from 20 000 cells by using an
EPICS XL flow cytometer (Beckman Coulter, USA) in the FL1
channel. Data analysis was performed with EPICS XL flow
cytometer software, and analytical gates were chosen as 1% of
control cells falling within the positive region.
HeLa cells (1 × 105) were first seeded onto sterile
coverglasses in a 6-well plate and cultured overnight to about
60% confluence in complete DMEM. For CLSM observation,
plasmid DNA (0.1 mg ml−1) solution was mixed with EtBr
(0.1 mg ml−1) aqueous solution at a volume ratio of 1:1,
and maintained at room temperature protected from light for
30 min. EtBr, with the membrane impermeability to living
cells, is known to give amplificatory fluorescence only when it
is embedded into DNA molecules. Double staining TG/DNA
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complexes were then prepared by mixing EtBr-labeled DNA
with FITC-labeled TG NPs, following section 2.4. The
cells were then incubated with double staining TG/DNA
complexes (100 μg ml−1) in serum-free DMEM for 2.5 h,
and subsequently cultured for another 2.5 h in serum-free
DMEM without nanoparticles. At the end of the time
point, samples were washed twice with PBS for 10 min
and fixed in paraformaldehyde (4% in PBS) for 30 min at
room temperature. After washing twice with PBS, Hoechst
33258 (10 μg ml−1) was added and maintained for 20 min
for nucleus staining and then washed twice with PBS. For
multi-color confocal microscopy, samples were excited with
488 nm for FITC and 590 nm for EtBr, respectively, on
an inverted laser confocal scanning microscope (Fluoview
FV1000, Olympus, Japan) using a Plan-Apochromat 60 × 0.7
NA lens. Images were captured by multi-tracking to avoid
bleed-through between the fluorophores and further processed
and merged with the Fluoview 1.5 Viewer software.
2.7.4. Endocytosis mechanism. HeLa cells (3 × 105) were
plated onto 30 mm cell culture coverslips and cultured at
37 ◦C overnight. Cells were then incubated with FITC-labeled
TG NPs (100 μg ml−1) in a serum-free medium, respectively,
together with Alexa Fluor® 546-transferrin (50 μg ml−1) and
Alexa Fluor® 594-Ctx B (10 μg ml−1) for 5 h at 37 ◦C (except
for the low-temperature 4 ◦C incubations). After washed three
times with PBS to remove extracellular bound NPs. HeLa cells
were first fixed with paraformaldehyde (4% in PBS) for 30 min
and then stained with Hoechst 33258 (10 μg ml−1) for another
20 min. After washed twice with PBS, the cells were observed
with an inverted SP2-MP2 laser confocal scanning microscope
(Leica, Germany) equipped with a Plan-Apochromat 100×1.4
NA lens (λex, 488 nm and λem, 520 nm for FITC; λex, 556 nm
and λem, 573 nm for Alexa Fluor® 546; λex, 590 nm and λem,
617 nm for Alexa Fluor® 594; λex, 365 nm and λem 465 nm
for Hoechst 33258). Images were captured by multi-tracking
to avoid bleed-through between the fluorophores and further
processed and analyzed with Leica CLSM software.
The endocytosis pathways were also investigated as
follows: (1) cellular incubation was carried out as described
above with the solution kept at 4 ◦C, instead of the regular
37 ◦C condition. (2) For the ATP-depletion studies, the
cells were pre-incubated in PBS, supplemented with NaN3
(50 mmol l−1) and 2-DG (0.5%) for 2 h at 37 ◦C, followed by
incubation in a solution of FITC-labeled nanoparticles. (3) The
inhibition of lipid-raft-mediated endocytosis was carried out
by cholesterol depletion, in which cells were pretreated with
β-CD (10 μmol l−1) in PBS for 2 h at 37 ◦C, prior to FITC-
labeled nanoparticle addition. (4) The inhibition of clathrin-
mediated endocytosis was carried out by pre-incubating cells
with Cpz (30 μmol l−1) in PBS for 2 h at 37 ◦C, before
exposure to nanoparticles. Once treatment was complete, cells
were incubated with FITC-labeled nanoparticles, followed by
analysis by an EPICS XL flow cytometer (Beckman Coulter,
USA), following section 2.7.3.
2.7.5. In vitro transgene expression. HeLa cells were first
seeded at a density of 5 × 104 cells/well in a 6-well culture
plate for 24 h, prior to the transfection experiments. After
removing the medium and washing with PBS twice, 1 ml of
serum-free DMEM medium containing TG/DNA complexes
was added. After transfection up to 26 h, the medium
was replaced with complete DMEM medium containing 10%
FBS, and the cells were allowed to grow for an additional
36 h. The β-galactosidase (β-gal) expression was measured
with a commercial β-gal reporter gene colorimetric detection
kit and performed according to the manufacturer’s protocols
with a microplate reader (Bio-rad 680, USA) at 415 nm.
Each transfection experiment was carried out in triplicate and
the transfection activity was expressed as the amounts of 0-
nitrophenyl-b-D-galactopyranoside (ONPG) hydrolyzed by β-
gal per 106 cells.
2.8. Statistical analysis
The data were presented as mean and standard deviation
(SD) calculated over three data points at least. Statistical
significance of differences was evaluated by a two-tailed
unpaired Student’s t-test. A value of P < 0.05 was considered
significant.
3. Results
3.1. Synthesis of TG NPs
The aqueous synthetic approach developed in this work is
shown in scheme 1. At the initial acidic pH condition (within
30 min), GPSM was subjected to cleavage of the C–O bond in
the epoxy group [29]. The protonated epoxy group is activated
to attack nucleophilic groups like NH2 on the side chain of
gelatin so that GPSM molecules could be grafted to the gelatin
chains. Meanwhile, methoxy silane groups (Si–OCH3) of
GPSM were simultaneously hydrolyzed in this acidic solution
to give silanol groups (Si–OH). On adding APTMS to the
above precursor sol, the pH value of this sol was changed to 8–
9 immediately. The polymerization reaction was thus initiated
since the hydrolyzed molecules of GPSM and APTMS, once in
contact with the basic solution, start to co-condense, forming
a network of siloxane. It is thus likely that the hydrolysis and
condensation of the metal alkoxides and ring-opening reaction
of the epoxy groups yield a crosslinked network in the GS NPs
as illustrated in scheme 1.
The size and surface charge of the as-synthesized GS
and TG NPs were summarized in table 1. The surface
charge of GS NPs (G1, G2, G3 and G4) exhibited similar
values around +25 mV, whereas the size of GS NPs can
be readily controlled by tuning the compositions. As the
molar ratio of GPSM/APTMS = 1.9, the lower weight ratio
(59.1) of gelatin/GPSM resulted in bigger particles (222 ±
7 nm), whereas the higher ratio (177.3) yielded slightly smaller
particles (165 ± 5 nm). On the other hand, as the molar ratio
of GPSM/APTMS increased to 3.0, the size of NPs increased
to >300 nm. In addition, the polydispersity (PDI) tended to
increase when the mean size of GS NPs was increased. It has
been reported that transcytosis increases when the nanoparticle
diameter decreases and the small-sized particles (<200 nm)
were more efficient in targeting tumors compared to particles
6
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Figure 1. (a) SERS spectrum and (b) CLSM image of TG NPs.
FITC-labeled TG NPs present as green dots in CLSM image.
with larger sizes [30]. Moreover, silica NPs with an average
diameter of 200 nm promote the delivery of gene transfection
to the highest degree as compared with the smaller silica
NPs [18]. Thus, GS NPs with the appropriate diameter of
165 ± 5 nm were thus used to synthesize TG NPs.
It has been demonstrated that Tat peptide has the ability to
deliver therapeutic cargo, while avoiding bringing non-linked
molecules into the cells [31]. It is thus necessary to covalently
couple Tat peptide onto GS NPs. As shown in scheme 1,
the immobilization of thiol (–SH) groups on GS NPs was
first achieved by the use of Traut’s reagent, which may react
spontaneously and efficiently with the primary amines at pH
7–9 [26]. In order to ensure effective thiolation, a twofold
molar excess of Traut’s reagent over NH2 groups (0.642 ±
0.048 mmol g−1 for G4 NPs) was used in our experiments. The
degree of thiolation, titrated colorimetrically by using the well-
known Ellman’s reagent, was to be 0.165 ± 0.006 mmol thiol
groups per gram GS NPs (G4). As expected, Npys-activated C-
terminal Cys containing Tat peptide (KYGRRRQRRKKRGC)
was then coupled to SH–GS NPs by forming disulfide bonds.
It is revealed from the spectrofluorimetry quantitative analysis
that the largest conjugating ratio of Tat peptide onto GS NPs
(Tat/GS) was 2.84 μmol g−1, though excess SH groups on
GS NPs had been provided during the synthesis processing.
This might be due to the effects of electrostatic repulsion and
steric hindrance between cationic GS NPs and cationic Tat
peptide. Successful coupling of Tat peptide onto GS NPs could
be respectively confirmed by SERS and CLSM, as shown in
figure 1. Two main bands in the Raman spectrum of TG NPs
could be distinguished (figure 1(a)): the band at 510 cm−1 was
assigned to the S–S symmetric stretching vibrational mode,
while the band at 640 cm−1 was attributed to the stretching
of C–S.
Although the results from the Raman spectrum proved
the existence of S–S bonds, one may question whether it
was derived from the conjugation of Tat peptide with SH–
GS NPs or from the linkage between the two remaining SH
residues on SH–GS NPs. In order to answer this question, we
used FITC-labeled Tat peptide instead of non-fluorescent Tat
peptide in the synthesis processing. Green fluorescent particles
could be easily observed in the CLSM image, as shown in
figure 1(b). Since GS NPs is not fluorescent, the bright colored
area qualitatively represents FITC-labeled Tat peptide. It is
thus clear that the integrating of Tat peptide onto GS NPs was
successful.
It is demonstrated from table 1 that the size of TG
NPs could be manipulated by the weight ratio of Tat/GS,
for example as Tat/GS = 1.58 μmol g−1, the particles
were smallest, in the size range of 158–176 nm (167 ±
9 nm). However, the Tat density on GS NPs has little
effect on the surface charge of TG NPs. On tuning the
weight ratio of Tat/GS from 0.63 to 2.84 (μmol g−1), the
mean surface charge was varied from 34.92 to 36.38 mV,
with no significant difference (P < 0.05). Nevertheless,
after modification with cationic Tat peptide, composed of five
arginine and three lysine residues, the surface charge of GS
NPs had increased by ∼10 mV. This is a predictive value for
the interfacial reactions between the Tat–GPs and negatively
charged DNA.
3.2. Cell compatibility
The cytotoxicity associated with nanoparticles has always been
a concern in their use as DNA carriers. The mitochondrial
function of the HeLa cells was measured by means of
the MTT assay after culturing in the presence of the TG
NPs (T2) for 24 h. As shown in figure 2(a), HeLa cells
showed no significant effect on mitochondrial activity at
concentrations <300 μg ml−1, which could be considered as
non-toxic. However, as the exposure concentration increased
to 600 μg ml−1, the mitochondrial function and viability of
HeLa cells decreased slightly (>70%). Hence, TG NPs may
cause dose-dependent cytotoxicity. This is consistent with
our earlier report for other NPs [32]. The mechanism of
cytotoxicity caused by TG NPs is not yet fully understood.
It seems that there would be two reasonable explanations
for the current observation. First, it could be expected that
intracellular NPs may affect cell viability by interacting with
cellular components, including cell membranes. Second,
the intracellular NPs are likely to have an effect on cellular
function (DNA replication, cell division, intracellular signal
transduction pathways, and so on), resulting in less cell
viability when compared to untreated cells [33]. Nevertheless,
the as-synthesized TG NPs exhibited a quite low cytotoxicity.
Namely, they had a high LD75 (lethal dose, 75%), at a
concentration level of 500 μg ml−1, while other inorganic
nanoparticles (Au NPs, CNTs, etc) have a much lower level,
about 50 μg ml−1 [15].
The above MTT assay could only detect cell necrosis.
Moreover, the cytotoxicity results as measured by the reduction
of the MTT substrate could, in theory, be ‘masked’ by cellular
proliferation [34]. To take into account the apoptotic or
necrotic nature of the nanoparticles’ cytotoxicity, the annexin
V-FITC/PI apoptosis assay was thus employed at 320 μg ml−1,
which could caused about 25% of HeLa cell damage, according
to MTT results. Meanwhile, lower dosage (160 μg ml−1)
with non-toxicity (cell viability >90%) was also evaluated to
understand whether the nanoparticles could cause cell damage
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Figure 2. (a) Normalized dose–response for cell viability of TG NPs by MTT assay. Bars represent the corresponding standard deviations
(n = 5). (b)–(d) Quantitative evaluation of cell apoptosis/necrosis caused by TG NPs. The flow cytometric scatter plots for 20 000 HeLa cells
were obtained using (b) non-treatment, (c) 160 μg ml−1 TG NPs and (d) 320 μg ml−1 TG NPs, respectively. I: early apoptotic cells; II: late
apoptotic cells; III: healthy cells; IV: necrotic cells.
through apoptosis in cells. It is believed that the combination
of these two different methods adds reliability to the final
evaluation of the cytotoxicity profiles of TG NPs formulations.
In the early stages of apoptosis, phosphatidylserine (PS) is
translocated from the inner side of the plasma membrane
to the outer layer. Annexin V with a high affinity for PS
can therefore be used as a sensitive probe for the exposure
of PS on the cell membrane and hence as a marker of
apoptosis [35]. Propidium iodide (PI), however, was used
to access the cell viability for its membrane impermeability
to living cells [36]. The degree of apoptotic cells was
examined by fluorescence-activated cell sorting (FACS), and
the results were shown in figures 2(c) and (d). Healthy cells are
presented as annexin V − /PI − (III); apoptotic cells express
phosphatidylserine, but have preserved membrane integrity
(annexin V +/PI–; I), while necrotic cells with damaged
membrane stain for both annexin V and PI (annexin V + /PI+;
II). In comparison with the negative control group (without
exposure to TG NPs, figure 2(b)), the population of living
cells, treated with TG NPs at 160 μg ml−1 and 320 μg ml−1
decreased by 25.9% and 30.1%, respectively. It is also
indicated that the early apoptotic population was increased
when cells treated increased to 17.2% and 26.2% for treating
with TG NPs for 24 h at 160 μg ml−1 and 320 μg ml−1,
respectively. Therefore, a slight perturbation of the plasma
membrane occurred in the presence of TG NPs. Nevertheless,
this event did not significantly induce cell necrosis (<10%
of 20 000 cells), which had parallel results with the MTT
assay.
3.3. Cellular uptake of TG NPs
Once cationic nanoparticles adhered to the cell surface, they
may be internalized into the cell. As shown in CLSM images
(figure 3), all of FITC-labeled Tat peptide, GS NPs and TG
NPs could be internalized into HeLa cells. However, less GS
NPs were found in the intracellular region than Tat peptides
and TG NPs. It is thus speculated that the cellular uptake of
nanoparticles might be promoted by Tat peptide.
Despite the great potential of Tat peptide in the
biomedical field, little is known about the mechanism of its
internalization [37]. The most recent studies indicated that Tat
peptide has strong interactions with the phosphate groups on
both sides of the lipid bilayer. The insertion of charged side
chains nucleate the formation of a transient pore, followed by
the translocation of Tat peptide into cells by diffusing on the
pore surface [37]. However, this transient pore mechanism is
unlikely to be applied for TG NPs (∼200 nm in diameter). One
possible pathway for nanoparticles to enter cells is either by
phagocytosis or endocytosis. Phagocytosis generally involves
the uptake of particles larger than 500 nm. Therefore GS or TG
NPs are thought to be mainly endocytosed since their particle
size is ∼200 nm.
Endocytosis is an energy-dependent uptake that is
hindered when incubations are carried out at low temperature
(4 ◦C instead of 37 ◦C) or in ATP (adenosine triphosphate)-
depleted environments [38]. Cellular incubations with TG
NPs were further carried out at 4 ◦C, and with cells pretreated
with NaN3 and 2-DG in parallel with our regular incubation
conditions. The treatment with NaN3 and 2-DG is known
to disturb the production of ATP in cells, thus hindering
8
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Figure 3. Cellular uptake of Tat peptide, GS NPs and TG NPs in HeLa cells. (a) HeLa cells were cultured in the presence of FITC-labeled Tat
peptide and FITC-labeled GS NPs, respectively. (b) Co-localization of TG NPs with Alexa Fluor® 546-labeled transferring and Alexa Fluor®
546-labeled CTX-B in HeLa cells, respectively. The emissions for FITC and Alexa Fluor® 546 are green and red, respectively. Overlay of the
two fluorescent layers results in yellow fluorescent emission wherever overlapping is complete. Cell nucleuses are dyed in blue by Hoechst
33258. Scale bars represent 20 μm.
Figure 4. Cellular uptake mechanism of TG NPs as measured by flow cytometric analysis. (a) HeLa cells were incubated with FITC-labeled
TG NPs at 37 ◦C (brown), 4 ◦C (pink) or first pretreated for 1 h with NaN3/2-DG (blue), β-CD (green) or Cpz (red), followed by incubation in
a solution of TG NPs at 37 ◦C. Black line corresponds to untreated cells. (b) The inhibitory effect of 4 ◦C, NaN3/2-DG, β-CD or Cpz on the
cellular uptake of FITC-labeled TG NPs, compared to normal cellular uptake efficiency (37 ◦C). Means ± SD are indicated (n = 3).
the endocytotic pathway. Indeed, the cellular uptake of
FITC-labeled TG NPs, after incubation with cells at 4 ◦C
(23.66%) and ATP-depletion (25.42%) circumstances, was
dramatically lower than that at 37 ◦C (94.79%), as shown in
figure 4(b). These data therefore indicated endocytosis as the
internalization mechanism for the uptake of TG NPs at 37 ◦C.
As potential biological transporters, another issue
remaining to be addressed for TG NPs is the entry
mechanism that regulates the cellular internalization. The
endocytosis pathway encompasses several subcategories,
including clathrin-dependent receptor-mediated and clathrin-
independent endocytosis [38]. Internalization through the
clathrin-dependent endocytosis occurs when the clathrin
coat on the plasma membrane forms invaginations in the
membrane leading to the budding of clathrin-coated vesicles;
whereas clathrin-independent endocytosis can occur through
9
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Figure 5. Gel electrophoresis assay of TG/DNA complexes. lane 1:
naked DNA (ND); lanes 2–4: T1/DNA complexes; lanes 5–7:
T2/DNA complexes; lanes 8-10: T3/DNA complexes. Complexes
with TG/DNA weight ratio of 20 (lanes 2, 5, 8), 50 (lanes 3, 6, 9)
and 100 (lanes 4, 7, 10) were investigated in deionized water.
the caveolae or lipid-raft pathway [38]. To assess the
role of clathrin in the internalization of TG NPs, HeLa
cells were incubated in solutions of FITC-labeled TG
NPs, together with Alexa Fluor® 594-labeled transferrin.
Transferrin is well known to be internalized through the
clathrin-mediated endocytosis pathway [39]. Indeed, it
is observed from CLSM images (figure 3(b)) that FITC-
labeled TG NPs (green) largely co-localized with Alexa
Fluor® 594-labeled transferrin (red) presented as yellow dots.
Moreover, after pretreating with Cpz, which is well known
to specially hinder clathrin-dependent endocytosis [40], the
cellular uptake of TG NPs significantly decreased to 51.86%
(figure 4).
To further elucidate the internalization mechanism of
TG NPs, we investigated the possibility of cellular entry
pathways through the clathrin-independent endocytosis. CTX-
B is known to be internalized through a lipid-raft-mediated
endocytosis pathway, and β-CD could disrupt the cholesterol
distribution within the cell membrane, thus hindering the
lipid-raft-dependent pathway [41]. As shown in figure 3(b),
FITC-labeled TG NPs (green) had much co-localization
with Alexa Fluor® 594-labeled CTX-B (red), presented
as yellow dots. We further observed that the cellular
uptake level from β-CD treated cells dramatically plunged
to 6.96% (figure 4). Taken together, our experimental
data suggested that cellular internalization of TG NPs is
through the clathrin- and lipid-raft-dependent endocytosis
pathway.
3.4. DNA condensation, stability, and release
A critical requirement for cationic nanoparticles for effective
gene delivery is their ability to condense string-like DNA
molecules into compact nanosized particles suitable for
cellular uptake [42]. As shown in table 1, T2 NPs with
Tat/GS = 1.58 (μmol g−1) led to a more compact TG/DNA
nanocomplex (D2), in the size range of 211–215 nm (213 ±
2 nm). Moreover, after loading with DNA, the surface charge
of nanoparticles decreased from 34–36 to 20–22 mV. It is
thus thought that, upon self-assembly of DNA and TG NPs,
the highly negative charge of DNA is neutralized rapidly
and the surface charge of the nanocomplex becomes positive.
This positive surface charge might increase the ability of the
TG/DNA complexes to adhere to the cell surface, which
consequently facilitates uptake by the cell.
The condensation capability of TG NPs with pDNA was
also evaluated by using agarose gel electrophoresis. It was
observed in figure 5 that, while free pDNA (lane 1) moved at
its usual position, pDNA complexed with TG NPs exhibited a
decreased mobility in an electromobility shift assay (lanes 2–
10). Complete retardation of the pDNA was achieved at the
weight ratio of TG/DNA = 100. This finding was in good
agreement with data obtained from dynamic light scattering
(table 1), since as the weight ratio of TG/DNA < 50, the
size of particles increased to more than 1 μm. Moreover, since
the electrostatic interaction is a critical force to drive pDNA to
approach TG NPs (∼ + 35–36 mV), Tat density on GS NPs,
in the range of 0.63–2.84 μmol g−1, was not found to have a
significant impact on the pDNA condensation ability.
For effective gene expression, the DNA in the gene vehicle
should be protected from degradation by enzymes [9–13].
In order to see the level of protection being offered to the
encapsulated DNA, TG/DNA complexes and naked plasmid
DNA were exposed to serum components or DNase I
treatment, followed by electrophoresis on 1% agarose gel
(figure 6, lanes 5–6). In contrast to the control naked plasmid
DNA (figure 6, lanes 2–3), TG/DNA complexes protected
the incorporated plasmid DNA efficiently (figure 6, lanes 5-
6). In order to test the functionality of the complexes in the
presence of serum components, HeLa cells were transfected
with TG/DNA complexes and showed successful expression
of β-galactosidase (data not shown).
In order to improve the efficiency of gene transfection,
it is necessary to find a right balance between the stability
Figure 6. (a) Reduction destabilizes TG/DNA (D2) complex in the presence of 10% FBS, 0.125 U DNase I or NaCl solutions. Lane 1: naked
DNA only; lanes 2–3: naked DNA with 10% FBS and DNase I, respectively; lane 4: D2 complex only; lanes 5–6: D2 complex with 10% FBS
and DNase I, respectively; lanes 7–9: D2 complex with 300, 150 and 50 mmol l−1 NaCl, respectively. (b) PicoGreen quantitative assay of
pSV β-gal release from D2 complex in 50, 150 and 300 mmol l−1 of NaCl aqueous solutions.
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Figure 7. Internalization and intracellular distribution of TG/DNA complexes. HeLa cells were transfected with the complexes of
FITC-labeled TG NPs (green) and EtBr-labeled pDNA (red). Cell nuclei were dyed in blue by Hoechst 33258. Scale bars represent 10 μm.
and release of pDNA in the gene delivery system. As
shown in figure 6(a), at high salt (NaCl) concentration
(>150 mmol l−1), a part of the plasmid DNA was released
from the complexes and appeared as supercoiled structures
(lanes 7–8). The release of DNA from TG NPs in the presence
of varying concentrations of NaCl was also quantified by
PicoGreen assay and the results were shown in figure 6(b).
TG/DNA nanocomplexes were stable in 50 mmol l−1 NaCl
aqueous solution. On increasing the concentration of NaCl to
150 mmol l−1, TG NPs gradually released the payload content
within 24 h, whereas in the presence of 300 mmol l−1 NaCl,
a rapid release within 1 h was observed. Hence, the presence
of ions, which is likely to destroy the electrostatic interactions
between TG NPs and DNA, could enhance the pDNA release
from TG/DNA nanocomplexes.
To clarify intracellular traffic of TG NPs, doubly
fluorescently labeled TG/DNA nanocomplexes (FITC-labeled
TG NPs and EtBr-labeled DNA) were prepared at a TG/DNA
weight ratio of 100:1 and their intracellular distributions were
observed by CLSM. It is revealed from figure 7 that TG/DNA
nanocomplexes (yellow dots) were internalized in HeLa cells
rather than adsorbed on the cell surface within 5 h. It
is reasonable to believe that, though some pDNA (∼20%,
figure 6(b)) might be released from TG NPs out of cells due
to the ionic destabilizer in physiological fluids, most of the
TG/DNA nanocomplex could, however, diffuse throughout
the cytoplasm and distribute in subcellular organelles in a
punctate manner (figure 7). Previous literature indicated
that the internalized nanoparticles might be first trapped in a
stable form in endosomes, and then escape from endocytic
vesicles via membrane fusion or proton sponge processes [15].
As indicated in figure 7, TG/DNA nanocomplexes (yellow
dots) were partly enriched in a Hoechst 33258-labeled cell
nucleus (blue) in 5 h. Hence, TG NPs might be able to
escape from endosomes, though their intracellular traffic is
not yet fully understood. Moreover, a part of encapsulated
DNA (red dots) could be observed to be detached from TG
NPs (green dots) in the cytoplasm or nucleus, which is in
concert with the release results (figure 6). It is not clear
when the loaded pDNA was dissociated from the TG NPs,
possibly during the nanocomplexes translocation in cytoplasm
into the importing into the nucleus or during the rupture of
the endosomal membrane [15]. When the DNA is liberated
into the cytoplasm, it has to be transferred to the nucleus for
efficient gene transfection. The fact that TG NPs encapsulated
DNA (yellow dots) mainly congregated in the perinuclear area
(enlarged picture in figure 7) makes us speculate that, probably
due to the ions’ impact, DNA could released from TG NPs just
at the import into the cell nucleus, so that the DNA could be
protected until its entrance into the nucleus.
3.5. In vitro transgene expression
In vitro transfection efficiency of TG/DNA nanocomplexes
with HeLa cells was assessed by using a pSV β-gal
assay. Figure 8(a) demonstrates that TG/DNA nanocomplexes
could provide high-level gene delivery to HeLa cells when
TG/DNA = 100:1 (g g−1) and Tat/GS = 1.58 (μmol g−1),
which is about 1.3-fold transfection efficiency of the
commercially available transfection reagent Lipofectamine™ .
However, as TG/DNA < 50:1 (g g−1), the large size
(>0.8 μm, table 1) may limit the efficient cellular uptake
of TG/DNA complexes, and hence result in lower gene
transfer efficiency. Interestingly, with the highest Tat content
(Tat/GS = 2.84 μmol g−1), although the complexes have a
large size (>1 μm, table 1) at TG/DNA = 20:1 (g g−1),
the plasmid DNA still has a slight transfection capability.
Considering that Lipofectamine™ is a highly competent vector
used for in vitro DNA delivery, our results thus indicated
that TG NPs can offer an approach for possible gene delivery
vectors. Three reasons might account for this efficient gene
transfection mediated by TG NPs: (1) pDNA in the TG
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Figure 8. pSV β-gal gene was expressed in HeLa cells. Bars represent the corresponding standard deviations (n = 3). (a) In vitro transfection
efficiency of TG NPs with different ratios of Tat/GS (μmol g−1) and TG/DNA (g g−1), in comparison with Lipofectamine™ .
(b) Transfection efficiency as a function of DNA dose for TG NPs with different Tat/GS ratio (NPs/DNA = 100:1 g g−1, exposure
time = 11 h). (c) pSV β-gal gene was expressed in a time-dependent fashion (NPs/DNA = 100:1 g g−1, Tat/GS = 1.58 μmol g−1, DNA
dose = 1.0 g/well). (d) Expression of pSV β-gal gene at different serum concentrations (NPs/DNA = 100:1 g g−1,
Tat/GS = 1.58 μmol g−1, DNA dose = 1.0 μg/well, exposure time = 11 h).
NPs could be protected from degradation by enzymes and
serum (figure 6). (2) TG NPs as a non-viral gene delivery
system have low cellular toxicity and a high cellular uptake
(94.79%) which could effectively carry the DNA into cells.
(3) Tat cell-penetrating peptide is covalently coupled with
GS NPs, which makes gene carriers more easily enter cells
and overcome a variety of physicochemical barriers (i.e. the
plasma membrane, the cytoskeletal network and the nuclear
membrane) of transfection, and thus enhance the efficiency of
gene transfer [43].
Figure 8(b) illustrates the effect of Tat/GS ratio and DNA
dose on gene transfection and expression in HeLa cells. It
is indicated that higher gene transfection efficiency could be
obtained at 1 μg of DNA per well. It should be noted that,
with lower DNA dose (<0.5 μg/well), a higher Tat/GS ratio
(2.84 μmol g−1) might result in higher gene transfer. However,
as the DNA dose increased to 1.0 μg/well, the maximum
transfer efficiency was achieved by Tat/GS = 1.58 μmol g−1.
It is thus speculated that the Tat/GS ratio and the dose of
the loaded DNA possibly exist in a complicated relationship
involving synergetic and antagonistic effects. Considering this
perplexing effect, it is thus demonstrated that optimal gene
transfection/expression for this system could be obtained as the
DNA dose = 1.0 μg/well, Ta/GS = 1.58 (μmol g−1) and
TG/DNA = 100:1 (g g−1), respectively.
In order to obtain the best gene transfer efficiency, the
culture conditions were further optimized by investigating the
effects of exposure time and serum. The results given in
figure 8(c) show a trend that the expression level of transgene
increased with increasing exposure time of cells to TG/DNA
complexes. Optimal exposure time for transfection occurred
with 11 h and longer exposure time did not result in a better
gene transfer. This adverse effect was probably caused by long-
term absence of serum, which is necessary for cell growth and
gene transfer. We also investigated the effect of serum on the
transfection efficiency of TG/DNA nanocomplexes. As shown
in figure 8(d), the transfection efficiency of the TG/DNA
nanocomplexes was dramatically decreased in the presence
of serum. This could be interpreted in that, as TG/DNA
nanocomplexes were added into the serum-contained culture
medium, serum proteins might be quickly adsorbed onto
the surface of complexes and formed ternary protein–DNA–
TG complexes by electrostatic interaction [44]. This might
subsequently prevent the release of encapsulated pDNA,
dramatically reducing the transfection efficiency.
4. Conclusions
Gelatin–siloxane hybrid nanoparticles (GS NPs) with con-
trolled size and surface charge could be obtained through a
two-step sol–gel process, and further thiolated successfully
by using Traut’s reagent. The thiolated GS NPs were then
used to prepare Tat–GS (TG) with a size of about 200 nm
and positive surface charge. The as-synthesized TG NPs
vesicles are biocompatible, and have high affinity to bind
with DNA through electrostatic interaction. The transfection
experiments show that the TG NPs as vectors can enhance
gene transfection efficiency compared to that of a commercial
reagent. Therefore, such a synthesized Tat peptide decorated
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gelatin–siloxane nanoparticles could represent a new type of
non-vector for the delivery of therapeutic DNA.
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PréatL V 2006 Nanoparticles as potential oral delivery
systems of proteins and vaccines: a mechanistic approach
J. Control. Release 116 1–27
[31] Wadia J S and Dowdy S F 2002 Protein transduction
technology Curr. Opin. Biotechnol. 13 52–6
[32] Ren L, Huang X L, Zhang B, Sun L P, Zhang Q Q, Tan M C
and Chow G M 2008 Cisplatin loaded Au–Au2S
nanoparticles for potential cancer therapy: cytotoxicity, in
vitro carcinogenicity, and cellular uptake J. Biomed. Mater.
Res. 85A 787–96
[33] Rudge S R, Kurtz T L, Vessely C R, Catterall L G and
Williamson D L 2000 Preparation, characterization, and
performance of magnetic iron–carbon composite
microparticles for chemotherapy Biomaterials 21 1411–20
13
Nanotechnology 19 (2008) 445103 Z-Y Wang et al
[34] Eyles J E, Bramwell V W, Singh J, Williamson E D and
Alpar H O 2003 Stimulation of spleen cells in vitro by
nanospheric particles containing antigen. J. Control. Release
86 25–32
[35] Yao G H, Ling L J and Luan J F 2007 Nonylphenol induces
apoptosis of Jurkat cells by a caspase-8 dependent
mechanism Int. Immunopharmacol. 7 444–53
[36] Gillan L, Evans G and Maxwell W M C 2005 Flow cytometric
evaluation of sperm parameters in relation to fertility
potential Theriogenology 63 445–57
[37] Herce H D and Garcia A E 2007 Molecular dynamics
simulations suggest a mechanism for translocation of the
HIV-1 TAT peptide across lipid membranes Proc. Natl Acad.
Sci. USA 104 20805–10
[38] Schmid S L and Carter L L 1990 ATP is required for
receptor-mediated endocytosis in intact cells J. Cell Biol.
111 2307–18
[39] Van Dam E M and Stoorvogel W 2002 Dynamin-dependent
transferrin receptor recycling by endosome-derived
clathrin-coated vesicles Mol. Biol. Cell 13 169–82
[40] Von Gersdorff K, Sanders N N, Vandenbroucke R,
De Smedt S C, Wagner E and Ogris M 2006 The
internalization route resulting in successful gene expression
depends on both cell line and polyethylenimine polyplex
type Mol. Ther. 14 745–53
[41] Wang Y, Li D, Fan H, Tian L, Zhong Y, Zhang Y, Yuan L,
Jin C, Yin C and Ma D 2006 Cellular uptake of exogenous
human PDCD5 protein J. Biol. Chem. 281 24803–17
[42] Jiang L, Qian F, He X, Wang F, Ren D, He Y, Li K, Sun S
H and Yin C H 2007 Novel chitosan derivative nanoparticles
enhance the immunogenicity of a DNA vaccine encoding
hepatitis B virus core antigen in mice J. Gene Med.
9 253–64
[43] Choi H S, Kim H H, Yang J M and Shin S H 2006 An insight
into the gene delivery mechanism of the arginine peptide
system: role of the peptide/DNA complex size BBA-Gen.
Subjects 1760 1604–12
[44] Hussain N, Singh B, Sakthivel T and Florence A T 2003
Formulation and stability of surface-tethered
DNA–gold–dendron nanoparticles Int. J. Pharm. 254 27–31
14
